Abstract
Advanced Therapy Medicinal Products (ATMPs) — gene therapy medicinal products, somatic cell therapy medicinal products, and tissue engineered products — are currently the most innovative drug products and hold promise to offer cure for a variety of diseases for which there are no satisfactory therapies. They have therefore elicited considerable interest and debate. The European Regulation on ATMPs provides a regulatory framework for these innovative medicines, and since 2009 the Committee for Advanced Therapies (CAT) at the European Medicines Agency (EMA) has started its work. The CAT is a multi-disciplinary scientific expert committee, representing all EU member states and EFTA countries, as well as patients’ and physicians’ associations. This book chapter briefly touches upon some of the diffi- culties developers of ATMPs may face, and the opportunities to approach the CAT as a regulatory advisor during development.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Amariglio N, Hirshberg A, Scheithauer BW, et al. (2009). Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 6(2): el000029
Baum C, Kustikova O, Modlich U, et al. (2006) Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther 17(3): 253–263
Broussau S, Jabbour N, Lachapelle G, et al. (2008) Inducible packaging cells for large-scale production of lentiviral vectors in serum-free suspension culture. Mol Ther 16(3): 500–507
Commission Directive 2009/120/EC of 14 September 2009 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use as regards advanced therapy medicinal products. Official Journal of the European Union 15.9.2009. L242/3-12 (2009)
Council Directive of 20 June 1990 on the approximation of the laws of the Member States relating to active implantable medical devices (90/385/EEC). Official Journal of the European Union, L 189, 20.7.1990, p 17 (1990)
Council Directive 93/42/EEC of 14 June 1993 concerning medical devices. Official Journal of the European Union, L 169, 12.7.1993, p 1 (1993)
European Medicines Agency (EMEA) (2008) Guideline on safety and efficacy follow-up — risk management of advanced therapy medicinal products EMEA/149995/2008. http://www.emea.europa.eu/pdfs/human/advancedtherapies/14999508enfin.pdf
European Medicines Agency (EMEA): Scientific Guidelines for Human Medicinal Products — Multidisciplinary Guidelines — Gene Therapy. http://www.emea.europa.eu/htms/human/hu-manguidelines/multidiscipline.htm
European Medicines Agency (EMEA): Committee for Orphan Medicinal Products (COMP): http://www.emea.europa.eu/htms/general/contacts/COMP/COMP.html
European Medicines Agency (EMEA) (2009) Committee for Advanced Therapies (CAT): Procedural Advice on the evaluation of advanced therapy medicinal products in accordance with Article 8 of Regulation (EC) No 1394/2007. EMEA/630043/2008. http://www.emea.europa.eu/pdfs/human/cat/63004308en.pdf
Hoos A, Parmiani G, Hege K, et al. (2007) A clinical development paradigm for cancer vaccines and related biologics. J Immunother 30(1): 1–15
Kohn DB, Candotti F (2009) Gene therapy fulfilling its promise. N Engl J Med 360(5): 518–521
Nishikawa S, Goldstein RA, Nierras CR (2008) The promise of human induced pluripotent stem cells for research and therapy. Nat Rev Mol Cell Biol 9(9): 725–729
European Medicines Agency (EMEA) (2008) Guideline on Human Cell-based Medicinal Products EMEA/CHMP/410869/2006. http://www.emea.europa.eu/pdfs/human/cpwp/41086906enfin.pdf
European Medicines Agency (EMEA) (2007) Committee for Advanced Therapies (CAT): Procedural Advice on the provision of scientific recommendation on classification of advanced therapy medicinal products in accordance with Article 17 of Regulation (EC) No 1394/2007. EMEA/99623/2009. http://www.emea.europa.eu/pdfs/human/cat/9962309en.pdf
High KA (2005) Gene therapy: the moving finger. Nature 435(7042): 577–579
Modlich U, Baum C (2009): Preventing and exploiting the oncogenic potential of integrating gene vectors. J Clin Invest 119(4): 755–758
Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Official Journal of the European Union 10.12.2007. L324/ 121-137 (2007)
Schüssler-Lenz M, Schneider CK (2010) Klinische Prüfung mit Arzneimitteln für Neuartige Therapien [Clinical trials with advanced therapy medicinal products]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 53: 68–74
Somia N, Verma IM (2000) Gene therapy: trials and tribulations. Nat Rev Genet 1(2): 91–99
VandenDriessche T, Collen D, Chuah MK (2003) Gene therapy for the hemophilias. J Thromb Haemost 1(7): 1550–1558
Wilson CA, Cichutek K (2009) The US and EU regulatory perspectives on the clinical use of hematopoietic stem/progenitor cells genetically modified ex vivo by retroviral vectors. Method Mol Biol 506: 477–488
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag/Wien
About this chapter
Cite this chapter
Jilma, B. (2010). Development of Advanced Therapy Medicinal Products — a case for early scientific advice. In: Müller, M. (eds) Clinical Pharmacology: Current Topics and Case Studies. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0144-5_21
Download citation
DOI: https://doi.org/10.1007/978-3-7091-0144-5_21
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-0143-8
Online ISBN: 978-3-7091-0144-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)